ReNetx Bio
  • Vision & Leadership
    • Our Team
    • Board of Directors
    • Advisory Board
    • Investors & Partners
  • Science & Pipeline
    • Mechanism
    • Pipeline
    • Publications
  • Clinical Trial
    • Clinical Trial
    • SCI Advisory Committee
    • Commitment to SCI
    • Expanded Access Policy
  • News
  • Contact
  • Vision & Leadership
    • Our Team
    • Board of Directors
    • Advisory Board
    • Investors & Partners
  • Science & Pipeline
    • Mechanism
    • Pipeline
    • Publications
  • Clinical Trial
    • Clinical Trial
    • SCI Advisory Committee
    • Commitment to SCI
    • Expanded Access Policy
  • News
  • Contact

Our Pipeline

Our lead program AXER-204 is in Phase 1/2 clinical trials and has Fast Track designation from FDA

Picture
​
​
​​
Contact
Financial Conflict of Interest Policy
 © 2021 ReNetX Bio, Inc. All Rights Reserved.